MLTX icon

MoonLake Immunotherapeutics
MLTX

Overview Fund Activity

115 hedge funds and large institutions have $3.43B invested in MoonLake Immunotherapeutics in 2024 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 48 increasing their positions, 31 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
115
Holders Change
+6
Holders Change %
+5.5%
% of All Funds
1.53%
Holding in Top 10
6
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+50%
% of All Funds
0.08%
New
22
Increased
48
Reduced
31
Closed
13
Calls
$11.3M
Puts
$8.56M
Net Calls
+$2.72M
Net Calls Change
+$1.67M

Top Buyers

1
Fidelity Investments
Fidelity Investments
Massachusetts
+$75.3M
2
PBA
Paradigm Biocapital Advisors
New York
+$45.5M
3
PCH
Polar Capital Holdings
United Kingdom
+$32.5M
4
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$19.7M
5
EC
EcoR1 Capital
California
+$18M

Top Sellers

1
BI
BVF Inc
California
-$108M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$19M
3
NNPTE
Nationale-Nederlanden Powszechne Towarzystwo Emerytalne
Poland
-$12.4M
4
Balyasny Asset Management
Balyasny Asset Management
Illinois
-$8.32M
5
Citadel Advisors
Citadel Advisors
Florida
-$7.37M
Name Holding Trade Value Shares
Change 		Shares
Change %
HF
126
HRT Financial
New York
– -$685K -13,592 Closed
Squarepoint
127
Squarepoint
New York
– -$323K -6,402 Closed
TRCT
128
Tower Research Capital (TRC)
New York
– -$84.3K -1,672 Closed
SSG
129
Summit Securities Group
New York
– -$5K -90 Closed
2 3 4 5
6